Growth & profitability
- Revenue has grown 29.5% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
NRIX Financials Nurix Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $84M | -$264M | 0.0% | -340.2% | -49.1% | -38.4% | -$263M | — | $247M |
| 2024 | $55M | -$194M | 0.0% | -390.5% | -36.7% | -28.9% | -$182M | — | $110M |
| 2023 | $77M | -$144M | 0.0% | -201.4% | -71.8% | -40.5% | -$90M | — | $55M |
| 2022 | $39M | -$180M | 0.0% | -476.0% | -59.4% | -43.3% | -$172M | — | $64M |
| 2021 | — | -$117M | — | — | -34.2% | -24.6% | -$90M | — | $81M |
| 2020 | — | -$43M | — | — | -14.9% | -10.9% | -$5M | — | $119M |
| 2019 | — | -$22M | — | — | 37.6% | -49.3% | -$1M | — | $35M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Aug '26 | $673M | $550M | 0.0% | 83.1% | 56.8% | 46.0% | $614M | — | $720M |
| May '26 | $9M | -$90M | 0.0% | -1041.7% | -22.2% | -16.7% | -$99M | — | $68M |
| Feb '26 | $6M | -$87M | 0.0% | -1479.4% | -18.1% | -13.7% | -$73M | — | $71M |
| Nov '25 | $14M | -$78M | 0.0% | -612.0% | -14.5% | -11.4% | -$73M | — | $247M |
| Aug '25 | $8M | -$86M | 0.0% | -1157.7% | -23.2% | -16.5% | -$60M | — | $78M |
| May '25 | $44M | -$43M | 0.0% | -109.7% | -9.7% | -7.3% | -$66M | — | $84M |
| Feb '25 | $18M | -$56M | 0.0% | -340.7% | -11.7% | -9.2% | -$65M | — | $76M |
| Nov '24 | $13M | -$59M | 0.0% | -486.7% | -11.1% | -8.7% | -$51M | — | $110M |
| Aug '24 | $13M | -$49M | 0.0% | -433.8% | -13.0% | -9.5% | -$45M | — | $99M |
| May '24 | $12M | -$45M | 0.0% | -401.4% | -12.0% | -8.7% | -$42M | — | $117M |
| Feb '24 | $17M | -$42M | 0.0% | -272.6% | -24.6% | -13.3% | -$45M | — | $50M |
| Nov '23 | $15M | -$42M | 0.0% | -299.1% | -20.9% | -11.8% | $24M | — | $55M |
| Aug '23 | $18M | -$37M | 0.0% | -216.7% | -15.8% | -12.0% | -$44M | — | $42M |
| May '23 | $31M | -$24M | 0.0% | -87.3% | -9.3% | -6.9% | -$20M | — | $59M |
| Feb '23 | — | -$41M | — | — | -14.9% | -11.0% | -$51M | — | $34M |
| Nov '22 | — | -$47M | — | — | -15.4% | -11.2% | -$41M | — | $64M |
| Aug '22 | — | -$46M | — | — | -13.3% | -10.0% | -$50M | — | $48M |
| May '22 | — | -$45M | — | — | -17.0% | -11.5% | -$36M | — | $42M |
| Feb '22 | — | -$43M | — | — | -13.9% | -9.7% | -$46M | — | $79M |
| Nov '21 | — | -$38M | — | — | -11.0% | -7.9% | -$32M | — | $81M |
Valuation over time
How the market has priced NRIX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 25.1× (Mar '23) to 22.1× (Nov '26).
P/S
Frequently asked questions
Is NRIX growing its revenue and profit?
Over the past 5 years, Nurix Therapeutics, Inc.'s revenue has grown 29.5% per year. These are computed facts, not advice.
How much debt does NRIX have?
As of FY2025, Nurix Therapeutics, Inc. reported — of total debt against $247M of cash.
What is NRIX's profit margin?
In FY2025, gross margin was —, operating margin -340.2%, and net margin -314.9%.
What is NRIX's P/E ratio?
Nurix Therapeutics, Inc.'s P/E (TTM) is 6.30 as of the 2026-11-03 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the NRIX stock page. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.